The COVID-19 pandemic has led to many changes in how pharmaceutical companies develop vaccines.

Combatting Future Viral Threats with Vaccine Advances

More technologies and treatments are emerging for COVID-19—along with new variants.

What’s Next for COVID-19 Vaccines and Variants?

Partnerships formed during the COVID-19 pandemic have provided a platform for change in assay development and transfers.

Key Elements for Assay Transfer Success

Topic

Felicity Thomas is Associate Editorial Director of Pharmaceutical Technology, Pharmaceutical Technology Europe, BioPharm International.

Articles

As company revenues are gaining a boost from COVID-19, the issue of pricing is being debated once more.

The Price Debate

Both Pfizer and Moderna have started clinical trials for their respective Omicron COVID-19 variant vaccine.

Pfizer and Moderna Begin Omicron Vaccine Trials

A report by international regulators reviews the effectiveness of current COVID-19 vaccines against the omicron variant.

COVID-19 Vaccination Offers Protection from Hospitalization due to Omicron Variant, According to Report

The agency’s COVID-19 task force says latest data shows use of COVID-19 mRNA vaccines during pregnancy is safe.

COVID-19 Vaccines Safe for Use During Pregnancy, EMA States

Hallie Forcinio is packing editor for Pharmaceutical Technology and Pharmaceutical Technology Europe, editorhal@sbcglobal.net.

Protective external packaging ensures COVID-19 vaccines arrive safely. 

Sustainable Shippers for Ultra-Cold Conditions

FDA amended it’s Emergency Use Authorization to shorten Moderna’s vaccine  booster dose interval from six to five months.

FDA Shortens Interval for Booster Dose of Moderna COVID-19 Vaccine

Intravacc is partnering with Leiden University Medical Center for the development and evaluation of a new intranasal coronavirus vaccine candidate in a clinical Phase I/II study. 

Clinical Trial on Intranasal Coronavirus Vaccine Set to Start

The agency is expanding the use of a single booster of the Pfizer-BioNTech vaccine to children ages 12–15 and is shortening the time between primary vaccination and booster to at least five months.  

FDA Expands Use of Pfizer-BioNTech COVID-19 Vaccine

Jill Wechsler is Pharmaceutical Technology's Washington Editor, jillwechsler7@gmail.com.

FDA authorized emergency use of Pfizer’s oral antiviral drug to make the drug available as quickly as possible. 

Here Come the COVID-19 Treatment Options

Moderna’s vaccine is weaker against the Omicron variant, but boosters can increase neutralizing antibody levels by as much as 83-fold.

COVID-19 Update

Combatting Future Viral Threats with Vaccine Advances

What’s Next for COVID-19 Vaccines and Variants?

Key Elements for Assay Transfer Success